Capivasertib Demonstrates Potential PFS Advantage in HR+ Advanced Breast Cancer
Combined treatment with capivasertib plus fulvestrant yielded a 5.5-month median progression-free survival for patients with HR+ advanced breast cancer.
Preoperative Treatment with Atezolizumab/Epirubicin Plus Trastuzumab/Pertuzumab Elicits High pCR Rate in Patients With Early HER2+ Positive Breast Cancer
Patients with early-stage HER2-positive breast cancer experienced a high rate of pathologic complete response with combined preoperative treatment with atezolizumab, epirubicin, trastuzumab, and pertuzumab.
Patients With De Novo or Late Recurrent Metastatic HR+ Breast Cancer Derive OS Benefit From Ribociclib/Letrozole
A subgroup analysis showed that patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy achieved better outcomes with ribociclib plus letrozole.
Olaparib Delivers PFS Benefit to Patients with gBRCA+, HER2– Metastatic Breast Cancer, Independent of ER Status
A post-hoc analysis suggests that olaparib may extend progression-free survival in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer, no matter their estrogen receptor expression level.
Trastuzumab Deruxtecan Exhibits Favorable Safety Profile in DESTINY-Breast04 Follow-Up
Trastuzumab deruxtecan outperformed investigators choice of therapy, in terms of safety, among patients with HER2-Low Metastatic Breast Cancer.
Heath-related QOL Maintained Longer With Trastuzumab Deruxtecan in HER2+ mBC
The time to definitive deterioration was delayed among patients receiving trastuzumab deruxtecan vs treatment of physician’s choice in all prespecified scales in DESTINY-Breast02.
Abemaciclib Displays Manageable and Reversible Safety Profile in monarchE PRO Findings for HR+/HER2– Breast Cancer
Patient-reported outcomes demonstrated a manageable safety profile with abemaciclib.
Patients With Metastatic Breast Cancer Maintain Quality of Life With Oral Elacestrant
Patient-reported outcomes among patients who received elacestrant were consistent with other endocrine therapies.
Regardless of HER2 Expression, Responses Are Showcased With Sacituzumab Govitecan in TNBC
Sacituzumab govitecan-hziy significantly improved progression-free survival in patients with HER2-low expressing TNBC and HER2-negative disease.
Entrectinib Generates Favorable Outcomes in NTRK Fusion+ Breast Cancer
Entrectinib elicited encouraging responses in patients with breast cancer that harbors NTRK fusions, according to updates from the phase 2 STARTRK-2 trial.
Trastuzumab Deruxtecan Continues to Elicit Responses in HER2+ Breast Cancer With Active Brain Metastases
Patients with HER2-positive breast cancer who also have brain metastases experienced clinical benefit with fam-trastuzumab deruxtecan-nxki in the phase 2 TUEXEDO-trial.
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC
2 Clarke Drive Cranbury, NJ 08512